Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of [⁶⁸Ga]Ga-PentixaFor in treatment-resistant hypertension and Primary Aldosteronism ...
TRAILBLAZER-2, a Phase 3 study, has enrolled 1,600 participants. Prescreening with plasma p-tau-181 helped select people with both amyloid and tau pathology. A secondary prevention trial, ...
BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology ...
AMPLIFY ( 64 Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants with Biochemical Recurrence of Prostate Cancer) is a non-randomised, single-arm, open-label, multi-centre, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results